Hospital Acquired Gramhyphen;Negative PneumoniasResponse Rate and Dosage Requirements with Individualized Tobramycin Therapy

摘要

Summarycolon;Individualized tobramycin therapy was systematically evaluated in 26 patients with gramhyphen;negative pneumonias involvingPseudomonas aeruginosaand other multiple antibiotichyphen;resistant pathogens. Patient prognoses were classified by underlying diseases, and response was determined according to previously established criteria. Twentyhyphen;three patients lpar;88percnt;rpar;, including all 11 cases involving multiple antibiotichyphen;resistant pathogens and 12 of 15 cases involvingPseudomonas aeruginosa, successfully responded to individualized tobramycin therapy. Tobramycin daily dosages and pharmacokinetic parameters demonstrated a wide interpatient variability. Measured peak and trough serum concentrations resulting from individualized dosage regimens trough serum concentrations resulting from individualized dosage regimens closely matched desired peak and trough concentrations. Clinical ototoxicity or nephrotoxicity were not observed. Individualizing dosage regimens was an important factor in obtaining therapeutic serum concentrations that may influence treatment response to tobramycin therapy.